Metal grafted graphene-based nanomaterials towards cancer theranostic efficacy
Prashant H. Gohil , Gopal Avashthi
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002346
Cancer is one of the leading global causes of mortality and morbidity, so it needs early diagnosis and therapies. Traditional diagnostic and therapeutic strategies are inadequate due to several limitations, such as poor specificity, systemic toxicity, and delays, while metal-grafted Gr nanostructures have emerged as promising theranostic platforms due to their unique electronic, optical, and structural properties. Metals such as Fe3O4, Au, Ag, TiO2, Pd, Pt, Bi, ZnO, and Cu grafted onto the Gr surface impart electronic modulation, enhance surface area, flexibility, conductivity, reactivity, biomolecular interactions, and biosensing, thereby enabling precise biomarker detection, targeted drug delivery, imaging, and photothermal/photodynamic therapy (PTT/PDT). Eco-friendly synthesis using plant extracts and microbes offers a sustainable and biocompatible alternative to conventional chemical synthesis. However, challenges remain, such as homogenous doping, synthetic complexity, long-term safety, and clinical scalability. Innovations such as scalable, cost-effective, biocompatible nanofibers, nanopapers, microfluidic, and wearable biosensors are being explored by incorporating AI and advanced diagnostic tools for advanced biomedical devices. In vitro, half maximum inhibitory concentrations (IC50) studies show that size- and dose-dependent nanohybrids such as Fe3O4-Gr, γ-Fe2O3-Gr, Au-Gr, and Bi-Gr exhibited safer responses at lower concentrations 10–200 µg/mL across HBE, MCF-7, HeLa B, and LNCaP cell lines. Bi-Gr was tested on human liver cancer (HepG2) cell line, which exhibits higher reactivity despite a safer profile of Bi at ~53–88 µg/mL. Pd-Gr and Pt-Gr significantly reduced viability in prostate and ovarian cancer cells at 10–50 µg/mL, while ZnO-Gr, Ag-Gr, and Cu-Gr showed safer activity at lower concentrations on MCF-7. In vivo studies remain limited; median lethal dose (LD50) values for Fe3O4-Gr and γ-Fe2O3-Gr were determined to be associated with rapid lethal biodistribution observed in the liver, lungs, and spleen. Metal-grafted Gr nanohybrids demonstrate immense potential for multifunctional cancer theranostics, though systematic in vivo toxicity studies still need to be explored by the intravenously administered route to lower the LD50 of nanohybrids for their clinical translation.
metal-grafted graphene nanohybrids / cancer theranostics / targeted drug delivery / reactive oxygen species (ROS)
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
Maruvada P, Wang W, |
| [14] |
Sarhadi VK, Armengol G. Molecular Biomarkers in Cancer. Biomolecules. 2022; 12: 1021. |
| [15] |
|
| [16] |
|
| [17] |
Cancer chemotherapy, immunotherapy, and biotherapy: principles and practice. In: |
| [18] |
Abbas Z, |
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
Xue H, Qiu B, Wang H, Jiang P, Sukocheva O, Fan R, |
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
Leech D. Affinity biosensors. Chem Soc Rev. 1994; 23: 205-13. |
| [30] |
|
| [31] |
Piezoelectric Transducers and Applications. In: Vives AA, editor. 2nd ed. Springer Berlin, Heidelberg; 2008. |
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
Nanotemplating: Engineering nanocomposite materials for the future. In: Yiu HHP, editor. 1st ed. Jenny Stanford Publishing; 2024. |
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
Rahimkhoei V, |
| [47] |
|
| [48] |
Rahimkhoei V, Akbari A, Jassim AY, Hussein UA, Salavati-Niasari M. Recent advances in targeting cancer stem cells by using nanomaterials. Int J Pharm. 2025;673:125381. |
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
Sharma S, Pandey MK. Radiometals in Imaging and Therapy: Highlighting Two Decades of Research. Pharmaceuticals (Basel). 2023; 16: 1460. |
| [56] |
|
| [57] |
Maucksch U, Runge R, Oehme L, Kotzerke J, |
| [58] |
|
| [59] |
|
| [60] |
Sridharan DM, Asaithamby A, Bailey SM, Costes SV, Doetsch PW, Dynan WS, |
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
|
| [72] |
|
| [73] |
|
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
Handbook on Nanobiomaterials for Therapeutics and Diagnostic Applications. In: Anand K, Saravanan M, Chandrasekaran B, Kanchi S, Panchu SJ, Chen Q, editors. Elsevier; 2021. |
| [78] |
|
| [79] |
|
| [80] |
|
| [81] |
|
| [82] |
Rayappan JBB, Nesakumar N, Ramachandra Bhat L, Gumpu MB, Babu KJ, Jayalatha JBB A. Electrochemical Biosensors with Nanointerface for Food, Water Quality, and Healthcare Applications. In: Bioelectrochemical Interface Engineering. John Wiley & Sons, Ltd; 2019. pp. 431-68. |
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
|
| [89] |
|
| [90] |
|
| [91] |
|
| [92] |
|
| [93] |
|
| [94] |
|
| [95] |
|
| [96] |
Hu K, Yang Z, Zhang L, Xie L, Wang L, Xu H, |
| [97] |
|
| [98] |
The Fullerenes. In: |
| [99] |
|
| [100] |
|
| [101] |
|
| [102] |
|
| [103] |
|
| [104] |
|
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
|
| [109] |
|
| [110] |
|
| [111] |
|
| [112] |
|
| [113] |
|
| [114] |
|
| [115] |
|
| [116] |
|
| [117] |
|
| [118] |
|
| [119] |
Bernal G, Aquea G, Ramírez-Rivera S. Metal-based molecules in the treatment of cancer: From bench to bedside. Oncol Res. 2025; 33: 759-79. |
| [120] |
|
| [121] |
|
| [122] |
|
| [123] |
|
| [124] |
|
| [125] |
|
| [126] |
|
| [127] |
|
| [128] |
|
| [129] |
|
| [130] |
|
| [131] |
|
| [132] |
|
| [133] |
|
| [134] |
|
| [135] |
|
| [136] |
|
| [137] |
|
| [138] |
|
| [139] |
|
| [140] |
|
| [141] |
Chemotherapy drugs. In: The War on Cancer: An Anatomy of Failure, A Blueprint for the Future. Dordrecht: Springer Netherlands; 2005. pp. 69-83. |
| [142] |
|
| [143] |
|
| [144] |
|
| [145] |
|
| [146] |
|
| [147] |
Espinosa-Cano E, Huerta-Madroñal M, Cámara-Sánchez P, Seras-Franzoso J, |
| [148] |
|
| [149] |
|
| [150] |
|
| [151] |
|
| [152] |
|
| [153] |
|
| [154] |
|
| [155] |
|
| [156] |
|
| [157] |
|
| [158] |
|
| [159] |
|
| [160] |
|
| [161] |
|
| [162] |
|
| [163] |
|
| [164] |
Liu L, Ma Q, Cao J, Gao Y, Han S, Liang Y, |
| [165] |
|
| [166] |
Koul B. Types of Cancer. In: Herbs for Cancer Treatment. Singapore: Springer Singapore; 2019. pp. 53-150. |
| [167] |
|
| [168] |
|
| [169] |
|
| [170] |
|
| [171] |
|
| [172] |
|
| [173] |
|
| [174] |
|
| [175] |
|
| [176] |
Zheng G, Zheng M, Yang B, Fu H, |
| [177] |
|
| [178] |
|
| [179] |
Assari P, |
| [180] |
|
| [181] |
|
| [182] |
|
| [183] |
|
| [184] |
|
| [185] |
|
| [186] |
|
| [187] |
|
| [188] |
|
| [189] |
|
| [190] |
|
| [191] |
|
| [192] |
|
| [193] |
|
| [194] |
|
| [195] |
Xiong H, Huang Z, Yang Z, Lin Q, Yang B, Fang X, |
| [196] |
Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models. In: Tuli HS, editor. 1st ed. Springer Singapore; 2020. |
| [197] |
|
| [198] |
Malik P, Gupta R, Malik V, |
| [199] |
|
| [200] |
|
| [201] |
|
| [202] |
Williams DF. Assessing the triad of biocompatibility, medical device functionality and biological safety. Med Devices Sens. 2021; 4: e10150. |
| [203] |
|
| [204] |
|
| [205] |
|
| [206] |
|
| [207] |
|
| [208] |
|
| [209] |
|
| [210] |
|
| [211] |
|
| [212] |
|
| [213] |
|
| [214] |
|
| [215] |
|
| [216] |
|
| [217] |
|
| [218] |
|
| [219] |
|
| [220] |
|
/
| 〈 |
|
〉 |